-4%
Obeticholic Acid is indicated for the treatment of primary biliary cholangitis (PBC) in adults.
- It can be used in combination with ursodeoxycholic acid (UDCA) for patients with an inadequate response to UDCA for at least 1 year.
- It can also be used as monotherapy for adults who are unable to tolerate UDCA.
- FXR 5mg Tablet acts as an FXR (Farnesoid X receptor) agonist.
- FXR is a nuclear receptor present in various tissues, including the liver, intestine, kidney, and adipose tissue.
- FXR plays a crucial role in regulating bile acid synthesis and transport, lipid metabolism, and glucose homeostasis.
- By activating FXR, Obeticholic Acid reduces de novo bile acid synthesis and increases the transport of bile acids out of hepatocytes, ultimately reducing hepatocyte exposure to bile acids.
